Delcath(DCTH)

• Growing revenue trajectory with 18.5x YoY growth (FY2024: $2M → FY2025: $37M) driven by HEPZATO commercialization
• Focused pipeline of 12 clinical programs with three Phase 3 assets targeting high-unmet-need oncology indications (ocular melanoma, hepatocellular carcinoma, metastatic liver cancers)
• Rare disease and orphan oncology focus offers meaningful clinical impact with smaller, more nimble teams than mega-cap pharma

Generated by Claude from Delcath's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Recent NDA approval driving 18.5x revenue growth; company's sole marketed product with 9-year patent protection.